Last reviewed · How we verify
Smallpox and Mpox Vaccine — Competitive Intelligence Brief
marketed
Live attenuated viral vaccine / Recombinant viral vaccine
Immunology / Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Smallpox and Mpox Vaccine (Smallpox and Mpox Vaccine) — SIGA Technologies. This vaccine stimulates the immune system to recognize and respond to smallpox and mpox viruses by presenting viral antigens.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Smallpox and Mpox Vaccine TARGET | Smallpox and Mpox Vaccine | SIGA Technologies | marketed | Live attenuated viral vaccine / Recombinant viral vaccine |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Live attenuated viral vaccine / Recombinant viral vaccine class)
- SIGA Technologies · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Smallpox and Mpox Vaccine CI watch — RSS
- Smallpox and Mpox Vaccine CI watch — Atom
- Smallpox and Mpox Vaccine CI watch — JSON
- Smallpox and Mpox Vaccine alone — RSS
- Whole Live attenuated viral vaccine / Recombinant viral vaccine class — RSS
Cite this brief
Drug Landscape (2026). Smallpox and Mpox Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/smallpox-and-mpox-vaccine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab